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Introduction: Nowdays, great effort is put into development of 
effective in vitro model for prediction of blood brain barrier (BBB) 
penetration of drugs. Recent investigation showed that gliclazide 
has protective effect on the brain of diabetic rat, but it has low BBB 
permeability that could be increased.
Aim: The aim of this study was to investigate whether in vitro models 
of gliclazide distribution in systems n-octanol/water and cyclohexane/
water are good in vitro models for the prediction of its penetration 
as well as for the prediction of influence of dexycholic acid (DCA) 
influence on penetration.
Patients (or Materials) and Methods: Distribution coefficient (logD) 
was determined using a …Flask shake “method. Partition profile was 
determined over physiological pH range (from pH 1.2 HCl solution, 
pH 4.5 acetate buffer, pH 6.8 and 7.4 phosphate buffer, and pH 7 
distilled water) for 5 combinations of n-octanol or cyclohexane with 
aquase gliclazide solution (10 µg/mL) of different pH and with or 
without the addition of DCA (0.5 mM) into n-octanol or cyclohexane 
phase. The analyses were done in triplicate for each pair of organic 
solvent/ water. Concentrations of gliclazide were determined using 
high-performance liquid chromatography. Values of logD at pH 7.4 
were compared with literature date of gliclazide BBB penetration and 
influence of DCA on it penetration.
Results: Higher partition into organic layer was found in system 
n-octanol/water than cyclohexane/water. Also DCA increased partition 
of gliclazide in system cyclohexane/water but not in system n-octanol/
water. Value of logD at pH 7.4 without DCA in organic layer in sys-
tem n-octanol/water was 0.34 (0.05) and in system cyclohexane/water 
was –0.74 (0.11). Value of logD at pH 7.4 with DCA in organic layer 
in system n-octanol/water was 0.54 (0.07) and in system cyclohex-
ane/water was 0.18 (0.01). Thus, partition of gliclazide in system 
cyclohexane/water better correlate with in vivo data where penetration 
of gliclazide was increased with DCA pretreatement, but in diabetic 
animals, penetration was increased in group with and without DCA 
pretreatment what this in vitro system could not predict.
Conclusion: Investigated system cyclohexane/water predicted poor 
gliclazide BBB penetration and the influence of DA on gliclazide pen-
etration but system n-octanol/water failed to do so. However, more 
substances are need to claim that system cyclohexane/water success-
fully could predict drugs BBB penetration.
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Introduction: Azathioprine (AZA) is an immunosuppressive drug 
widely used in inflammatory bowel disease (IBD). Few data on 
azathioprine (AZA) therapy IBD exist for children. We evaluated 
whether the 6-thioguanine nucleotides (6-TGN) level predicts AZA 
refractoriness in children with IBD and whether children benefit an 
AZA dose escalation.
Patients (or Materials) and Methods: Seventy-eight children with 
IBD initially treated with an AZA dose of 1.5 to 2.5 mg/kg/d were ret-
rospectively included. The dose was adjusted based on the clinical sta-
tus. 6-TGN and Me6-MPN thiopurine metabolites were determined 
by HPLC. The receiver operating characteristic curve and logistic 
regression were used to determine predictors for AZA resistance.
Results: Initially, 18 of 40 (45%) patients receiving a dose below 2 
mg/kg/d and 11 of 38 (28.9%) patients receiving a dose of 2 to 2.5 
mg/kg/d achieved remission. The 6-TGN level above 250 pmol/8.108 
RBCs was associated with a higher remission rate, although non-
significant. Among 35 patients with a dose escalation due to treat-
ment failure, 12 (34.3%) achieved remission (the median 6-TGN 
level increased from 260 to 394 pmol/8.108 RBCs (P = 0.002)), 23 
(67.6%) were AZA refractory. A 6-TGN level above 405 pmol/8.108 
RBCs was the only predictor for AZA resistance (sensitivity, 78.3%; 
specificity, 75%; OR, 10.8 [95% CI, 2.1–55.7], P = 0.004)).
Conclusion: Drug monitoring of thiopurine metabolites is useful to 
identify children with IBD resistant to AZA. Children who cannot 
achieve remission despite a 6-TGN level above 405 pmol/8.108 RBCs 
should receive alternative therapies.
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Introduction: Antibacterial drugs are among the most common med-
ications used by pregnant women. Although the medical literature 
generally defines nitrofurantoin as safe antibiotic during the first tri-
mester of pregnancy, lately new concerns of association between birth 
defects after exposure to nitrofurantoin during the first trimester of 
pregnancy have surfaced. We conducted a large population-based ret-
rospective cohort study to assess the association between exposure to 
nitrofurantoin during the first trimester of pregnancy (including cases 
of medical terminations of pregnancy or stillbirth) and birth defects.
Patients (or Materials) and Methods: A computerized database of 
medications dispensed from 1999 to 2009 to all women registered 
in the “Clalit” HMO, in the southern district of Israel, was linked 
with 2 computerized databases containing maternal and infant hos-
pitalization records. Associations between exposure to nitrofurantoin 
during the first trimester and birth defects were assessed. The follow-
ing confounders were controlled for: parity, maternal age, ethnicity, 
maternal pregestational diabetes, year of birth or medical pregnancy 
termination, and smoking.
Results: A total of 105,492 pregnancies were included in our 
research, of which 1112 pregnancies were pregnancy terminations 
because of medical reasons. A total of 1329 infants and abortuses 
Clinical Therapeutics
e88 Volume 35 Number 8S
had been exposed to nitrofurantoin during the first trimester of 
pregnancy. Exposure to nitrofurantoin was not associated with an 
increased risk of birth defects in general (adjusted OR, 0.850 [95% 
CI, 0.669–1.080]) or specific malformations.
Conclusion: First-trimester exposure to nitrofurantoin was not asso-
ciated with increased risk for major birth defects as well as other 
specific malformations.
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Introduction: Understanding the gap between evidence-based medi-
cine and clinical practice is necessary to improve clinical outcomes in 
children. This study aimed to investigate the most used drugs, ana-
lyzed in defined daily doses (DDD), in the Danish paediatric wards 
within 1 year.
Patients (or Materials) and Methods: Data were extracted from a 
Danish database, which contains information about the number of 
DDD sold to the hospital pharmacies including what is sold to the 
pediatric wards, hereby estimating the pediatric drug use. Two analy-
ses were made regarding the drug consumption. A main analysis cov-
ering the 90% most used drugs where the extent of off-label use and 
the number of drugs having a Pediatric Investigation Plan (PIP) were 
explored. Nationwide, 16 hospitals were included representing both 
general and specialized pediatric departments. Secondly, a test sample 
analysis was made regarding drug use during hospital admission, 
covering 80% of the pediatric standard medicine assortments from 
3 hospitals; results from the remaining hospitals are being prepared.
Results: One hundred drugs constituted the 90% most used drugs 
in the pediatric wards. Divided by anatomical classification (ATC), 
treatment of infections (J), drugs used for alimentary tract and metab-
olism problems (A), and antineoplastic and immunomodulating 
agents (L) were most prescribed. The subgroup L has not been among 
the most used ATC groups before, the expenses for this subgroup 
constitutes 25% of the entire pediatric medicine budget. Fifteen drugs 
(15%) were by all indications off label, the amount of DDD used off 
label accounted for 9.2%. A PIP existed on 25 drugs in total. The 
average time from central authorization to completed PIP was 8.5 
years, and 32% of the PIPs were completed by 2013. Preterm and 
newborns were included in 25% of the PIPs and adolescents in 64%. 
In the test sample 71% of the drugs were repeated when compared 
with the results from the main analysis. The immunomodulating 
agents were not included. Contrary to the main analysis, drugs aimed 
at the nervous system (N) were among the most used subgroups.
Conclusion: The PIP is a fairly new step toward evidence-based 
medicine ensuring the safety, efficacy, and positive risk-benefit bal-
ance by assessing clinical trials in children. However, only one fourth 
of 100 most used drugs in pediatric wards have a PIP and only 8 of 
these are completed. As a consequence, off-label drug use is frequent 
in Danish children and rational guidance regarding prescriptions in 
several areas is needed.
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Introduction: Daptomycin is a lipopeptide antibiotic with rapid con-
centration-dependent bactericidal action against Gram-positive organ-
isms. Target daptomycin plasma concentrations have been determined 
in animal models for some pathogens, but data on optimal exposure in 
humans are still lacking. Measurement of daptomycin plasma concentra-
tion is available at our institution since 2009 and is performed regularly. 
The aim was to assess variability of daptomycin plasma concentrations 
and the main determinants influencing daptomycin exposure.
Patients (or Materials) and Methods: We retrospectively collected 
data in patients with at least 1 determination of daptomycin plasma 
concentrations during the period of January 2009 to February 2012 
at the University Hospital of Zurich. Samples were analyzed by 
LC-MS/MS. Because daptomycin is mainly eliminated by the kid-
neys, exposure in patients with no renal replacement therapy (nRT), 
intermittent RT (iRT), and continuous RT (cRT) was compared. A 
trough level (Cmin) of at least 10 mg/L and a minimal peak level (Cmax) 
of 50 mg/L were defined as optimal based on animal data.
Results: Ninety patients were identified with a mean (SD) age of 
59 (16) years and a mean body weight of 74 (21) kg with 15 (16%) 
patients having a BMI > 30. The mean total daptomycin dose was 448 
(133) mg (range, 175–1000 mg). In 22%, daptomycin was adminis-
tered every 48 hours and in 1% every 36 hours. Mean Cmax was 66.2 
mg/L (n = 247; range, 20–236 mg/L) and mean Cmin was 16.7 mg/L 
(n = 116; range, 2–68 mg/L). Cmax and Cmin levels were significantly 
lower in cRT (52 [20] mg/L and 9.5 [7] mg/L, respectively) compared 
with nRT (75.6 [42] mg/L and 21.4 [16] mg/L, P < 0.0001). Cmin 
below 10 mg/L was found in 69% of cRT, in 35% of iRT, and 26% 
of nRT and Cmax was below 50 mg/L in 52% of cRT, 8% of iRT, and 
27% of nRT. When controlling for plasma creatinine and albumin 
concentration, dose interval, administered dose/kg and BMI, cRT 
remained significantly associated with an increased risk of a Cmin level 
below 10 mg/L (OR = 3.1; P= 0.001) compared with nRT. There was 
an inverse and independent association between administered dose/
kg and Cmax below 50 mg/L (OR = 2.0; P = 0.003). Trough levels 
> 20 mg/L were mainly seen in nRT patients with renal impairment 
with only 2 cases of mild CK elevation.
Conclusion: Daptomycin exposure is highly variable depending on 
renal function and renal replacement therapy used. Patients undergo-
ing cRT had the highest proportion of low daptomycin exposure with 
the highest risk for possible under dosing.
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